整理 | GLP1减重宝典内容团队 近期，司美格鲁肽因显著的减重效果备受关注，但随之而来的"跟风式用药"现象却令人担忧。 一些人将药物当作"应急瘦身针"，不规律注射甚 至自行停药，结果不仅体重反弹，不良反应也明显增多。 医学界纷纷呼吁：肥胖是一种慢性病，减重药物的使用必须严格遵循长期管理方案， 盲目追求短期效果往往会适得其反。 还有一些人达到平台期后，继续用同一剂量的司美格鲁肽大多只能维持原体重或逐渐失效，从而停止用药。这些做法都是不对的。下面就来分析 下理由。 ▍"打一针瘦五斤"？不可药物滥用 在朋友眼中，身高158cm、体重110斤的许女士并不胖，可她却对减肥有着强烈的渴望。她打完第一针司美格鲁肽后的第一周，体重就降到了106 斤，她满心期待能回到体重不过百的状态。 然而，中国医学科学院内分泌科的专家指出，司美格鲁肽主要是通过调节食欲、延缓胃排空来发挥减重作用的，只有维持稳定的血药浓度，才能 达到理想的减重效果。如果随意注射、中断用药，就会打破身体的代谢节奏，不仅会影响药物的疗效，还可能加重胃肠道的不良反应，甚至有可 能诱发胰腺炎等严重风险。 北京协和医院肥胖门诊的医生也强调，这类药物并非短期就能解决问题 ...

整理 | GLP1减重宝典内容团队 2026年1月23日，国家药品监督管理局药品审评中心（CDE）官网显示，众生药业旗下RAY1225注射液获批开展新的临床试验，用于治 疗肥胖合并阻塞性睡眠呼吸暂停。该适应症的获批，标志着RAY1225成为国内少数在肥胖相关并发症方向持续扩展布局的GLP-1类候选 药物之一，也是该产品获得的第4项临床适应症批准。此前，RAY1225已分别获批用于肥胖、2型糖尿病以及代谢功能障碍相关脂肪性 肝炎，适应症覆盖减重、血糖控制及代谢系统性疾病等多个关键领域。 | 首页 | 机构职能 | 新闻中心 | 政策法规 | 党建工作 | 信息公开 | 申请人之窗 | 办事服务 监督与反馈 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | ♀ 当前位置：信息公开 > > 临床试验默示许可 | | | | | | | 信息公开 | | | | | | | | | | 受理品种信息 | | 查询条 | 请输入萱询条件 | | | | | 萱 询 | | | | 件: | | | | | | | | 审评任务公示 | ...

Core Viewpoint - Novo Nordisk's oral GLP-1 weight loss drug, Wegovy, has exceeded market expectations with rapid prescription growth, outperforming its injectable version and competitors in the same category [4][6]. Group 1: Market Performance - In just two weeks post-launch, oral Wegovy achieved approximately 18,400 prescriptions, with some estimates nearing 20,000, compared to 1,600 for the injectable version and 7,300 for Eli Lilly's Zepbound during the same period [4]. - The strong performance of oral Wegovy is crucial for Novo Nordisk to regain its footing in the weight loss market, which has been challenged by Eli Lilly's competitive advantages [6]. Group 2: Product Attributes - Oral Wegovy received FDA approval in December 2025 as the first oral GLP-1 drug for obesity treatment, with a maximum daily dose of 25 mg and an indication for reducing cardiovascular risk, broadening its applicability [6]. - The pricing strategy for oral Wegovy is set at $149 per month for cash-paying patients, with a minimum of $25 for those with commercial insurance through the company's discount program, which is seen as a key factor for early adoption [6]. Group 3: Industry Implications - The rapid uptake of oral Wegovy signals strong market demand for oral GLP-1 weight loss drugs, potentially benefiting Eli Lilly's upcoming oral product, orforglipron [7]. - Analysts note that the competitive landscape is shifting from efficacy comparisons to factors like administration method, affordability, and long-term adherence, indicating a new phase in the weight loss drug market [8].

Core Viewpoint - The article emphasizes the importance of hydration for individuals using GLP-1 medications for weight loss, highlighting that adequate water intake can enhance the efficacy of the drugs and mitigate side effects [5][7][8]. Group 1: Importance of Hydration - Water constitutes about 20% of daily total water intake from food, and using GLP-1 medications may lead to reduced food intake and potential dehydration risks [5] - Proper hydration is crucial for digestion and drug metabolism, ensuring sufficient digestive fluids are available to aid in food breakdown and nutrient absorption [7] - Insufficient water intake can lead to constipation and bloating, which may hinder weight loss efforts [7] Group 2: Symptoms of Dehydration - Users of GLP-1 medications may experience mild dehydration, leading to symptoms such as headaches, muscle cramps, nausea, constipation, fatigue, and dizziness [8] - Dehydration can exacerbate common gastrointestinal side effects of GLP-1, such as nausea and constipation, making hydration particularly important for those experiencing vomiting or diarrhea [8] Group 3: Detoxification and Fat Metabolism - Water aids in the elimination of toxins released from fat cells during weight loss, preventing their accumulation and ensuring effective metabolism [9] - Adequate hydration is necessary for the body to metabolize fat efficiently, as insufficient water can slow down weight loss progress [10] Group 4: Energy Levels and Exercise Performance - Fatigue is a common side effect of dehydration and weight loss medications; drinking water can help restore energy levels [12] - Hydration is essential for muscle function, endurance, and recovery, especially when exercise is part of a weight loss plan [12] Group 5: Hydration Guidelines - There are no specific guidelines for water intake for individuals using GLP-1 medications, but general recommendations suggest women should consume about 91 ounces and men about 125 ounces of water daily [13] - Individual hydration needs may vary based on factors such as body size, other medications, outdoor temperature, and physical activity [13] Group 6: Monitoring Hydration - A simple method to check hydration status is by observing urine color; light yellow indicates adequate hydration, while dark yellow suggests a need for increased intake [14] - Keeping track of fluid intake and ensuring regular hydration throughout the day can help meet daily liquid goals [14]

以下文章来源于肥胖世界ObesityWorld ，作者肥胖世界 肽激素作为一类小分子（少于100个氨基酸）、低丰度物质，在调节能量平衡等多种生理功能中扮演关键角色，使其成为肥胖治疗的理想靶 点。自40年前发现调节食欲的神经肽Y以来，科学家已陆续发现12种参与食欲调节的肽类物质。尽管蛋白质组学研究已能从生物组织或血液中 检测和量化肽类，但由于其丰度低且难以区分生物活性片段与降解产物，肽类的发现和功能表征仍面临巨大挑战。历史上，具生物活性的肽类 主要通过从内分泌器官生化纯化获得，如从胰腺或肠道提取物中分离胰岛素、胰高血糖素和胃泌素，或从脑组织中提取神经肽Y和促性腺激素 释放激素。 2025年3月5日，斯坦福大学医学院Katrin J. Svensson教授团队在Nature在线发表重磅研究，通过人工智能技术首次报道了一种全新抗肥胖多 肽BRP（BRINP2-related peptide）。研究表明，BRP能在小鼠和猪模型中有效减少食物摄入并展现显著抗肥胖作用，且不引起恶心或厌恶反 应。机制研究发现，BRP给药能触发中枢神经系统FOS蛋白激活，其作用独立于瘦素、GLP-1受体和黑皮质素4受体信号通路。 肥胖世界O ...

Core Viewpoint - The global GLP-1 market is shifting, with multinational pharmaceutical companies increasingly focusing on Chinese biopharmaceutical assets, a trend expected to peak in 2025 and be confirmed in early 2026 [5] Group 1: Market Dynamics - The competition in the weight loss and metabolic disease market is evolving from single product competition to a comprehensive contest involving multiple mechanisms, indications, and long-term medication [5] - Multinational pharmaceutical companies are experiencing anxiety regarding pipeline breadth and technological reserves, with China emerging as a key source for supplementing GLP-1 pipelines [5] - Over the past decade, the role of Chinese innovative drug companies has shifted from introducing overseas technology to exporting self-developed assets [5] Group 2: Asset Development - Chinese companies have accumulated a number of candidates in the GLP-1 field, particularly in dual-target, triple-target, and oral formulations, with several in Phase II and III [5] - These assets are characterized by preliminary validation of scientific pathways and identifiable clinical risks, making them valuable for multinational companies to quickly fill their pipelines through licensing or acquisition [5] Group 3: Transaction Highlights - Novo Nordisk made a significant move by securing rights to a triple-target agonist, UBT251, with a payment structure of $200 million upfront and up to $1.8 billion in milestone payments, reflecting a strategic choice to rebuild its next-generation weight loss product lineup [7] - Regeneron entered a licensing agreement with Hansoh Pharma worth over $2 billion for a GLP-1/GIP dual-target agonist in Phase III, aiming to strengthen its position in the metabolic disease field [7] - Pfizer, after terminating two late-stage oral GLP-1 candidates due to safety issues, acquired Metsera for nearly $10 billion and entered a licensing agreement with YaoPharma for an early-stage oral GLP-1 candidate, demonstrating a cautious approach to re-entering the oral weight loss drug market [7] Group 4: Strategic Implications - These transactions signal that multinational pharmaceutical companies are preparing for the second phase of competition in the GLP-1 market, focusing on efficacy limits, medication convenience, long-term safety, and combination therapy potential [8] - The shift indicates a structural adjustment in the global pharmaceutical industry, with China transitioning from merely a clinical trial and production base to a significant technology supplier in key therapeutic areas [8]

Core Insights - The article discusses the impending patent expiration of GLP-1 drugs, particularly semaglutide, in March 2026, which is expected to trigger a significant shift in the Indian market for these weight loss and diabetes medications [4][6] - Indian pharmaceutical companies are preparing to enter the GLP-1 market aggressively, with several firms already obtaining regulatory approvals to sell semaglutide formulations, indicating a pre-launch state [6][7] - The market for GLP-1 drugs in India has seen explosive growth, with the segment's size increasing from approximately 1.86 billion INR in November 2022 to over 10 billion INR by November 2025, reflecting a more than fivefold increase in just three years [6] Industry Dynamics - The Indian GLP-1 market is characterized by a competitive landscape where original drug manufacturers, like Eli Lilly and Novo Nordisk, are actively trying to maintain their market share through price reductions and product line expansions [7] - The outcome of ongoing legal proceedings regarding semaglutide's patent will significantly influence the market dynamics, with a ruling expected before the patent expiration [4][7] - The demand for GLP-1 drugs in India is anticipated to surge once price barriers are lowered, as the country has one of the largest diabetic populations globally, coupled with rising obesity rates [6]

整理 | GLP1减重宝典内容团队 ▍老年人，能否将GLP-1药物作为新一代管理途径？ 随着GLP-1类减肥与降糖药物在美国迅速普及，越来越多65岁以上的 自从GLP-1类减肥药物在几年前迅速走红以来，克利夫兰诊所老年医学专家Chitra Ganta明显感受到，越来越多老年患者开始主动咨询这类药 物。 在获批用于体重管理之前，Ganta已多年将GLP-1药物用于糖尿病治疗，并亲眼见证其在改善血糖控制和代谢状态方面的积极效果。因此，当这 些药物被引入减重领域时，她认为这为长期受肥胖困扰的患者提供了新的可能。 Ganta表示，GLP-1受体激动剂在临床实践中帮助不少代谢紊乱患者改善了健康状况，尤其是在糖尿病和肥胖管理方面，提高了部分患者的生活 质量。"许多患者带着希望而来，而能够为他们提供一种新的医学工具，本身就很有意义。" 这一变化发生在肥胖问题持续加剧的背景下。美国疾控中心数据显示，截至2023年，60岁及以上人群中，接近四成被归类为肥胖。研究表明， 肥胖和脂肪过多在老年阶段带来的健康影响尤为显著，不仅增加心血管疾病、代谢性疾病、呼吸系统和内分泌疾病的风险，也与多种癌症相 关。同时，肥胖还会限制行动能力，加重 ...

Core Viewpoint - Tirzepatide is emerging as a leading candidate for treating overweight and obesity due to its significant weight loss effects and improvements in various metabolic parameters [5][7][8]. Group 1: Clinical Efficacy and Market Demand - In the SURMOUNT-5 clinical study, Tirzepatide demonstrated an average weight loss of 20.2% over 72 weeks in overweight adults with related comorbidities, significantly surpassing Semaglutide's 13.7% [8]. - Tirzepatide received approval for obesity treatment in November 2023 and for moderate to severe obstructive sleep apnea in December 2024, marking it as the first drug approved for this condition [8]. Group 2: Mechanism of Action - Tirzepatide activates GIP/GLP-1 receptors, promoting insulin secretion, inhibiting glucagon release, delaying gastric emptying, and suppressing appetite, which collectively aid in weight management and blood sugar control [9]. Group 3: Indications for Use - Tirzepatide is indicated for type 2 diabetes patients, particularly those with poor blood sugar control despite other treatments and those needing weight loss [10]. - It is also indicated for obesity management in adults with a BMI of ≥28 kg/m² or ≥24 kg/m² with at least one weight-related comorbidity [11]. Group 4: Contraindications and Cautions - Tirzepatide is not suitable for type 1 diabetes patients, those with acute diabetic ketoacidosis, severe gastrointestinal diseases, or a history of medullary thyroid carcinoma [12][13][14].

以下文章来源于肥胖世界ObesityWorld ，作者欢迎订阅 肥胖世界ObesityWorld . 《肥胖世界》Obesity World - 同步传真肥胖及代谢国际新学术进展，为医学减重临床、教研人员搭建一座与国际接轨的桥梁，「每医健」旗下内容平台。 面对琳琅满目的美食诱惑，虽然偶尔放纵一两口不会立刻变胖，但若是管不住嘴，体重难免悄然上升。尤其在如今获取食物变得前所未有容易 的时代，学会适时停下筷子，对每个人都至关重要。 世界卫生组织的最新数据显示，随着生活方式的转变，肥胖已成为全球性的公共健康难题——全球成年肥胖人数已超过8.9亿，占总人口的 13%。尤其在过去四十年里，包括中国在内的许多国家和地区，肥胖人群激增，相关的心血管等慢性疾病风险也随之水涨船高。 众所周知，减肥的核心策略是"少吃多动"，但真正做到却并不容易。对许多人来说，单靠生活方式调整很难实现理想体重，这时药物干预就成 为有效选择。近年来，全球爆火的"网红"减肥药司美格鲁肽，凭借显著的减重效果成为焦点，其主要机制就是通过抑制食欲帮助人们"管住 嘴"。 近日，顶级学术期刊《细胞》发表的一项新研究，为开发全新"管住嘴"类减肥疗法带来了启发。美国 ...